ClinicalTrials.gg
CompletedNCT05498155OlympiaNUpdated Sep 25, 2026Results posted

Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer

A Phase 2 interventional study of Neoadjuvant Olaparib monotherapy group and Neoadjuvant combination therapy with olaparib plus durvalumab in Breast Cancer, sponsored by AstraZeneca. Completed at 36 sites in 9 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Updated Sep 25, 2026Now CompletedResults posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing olaparib in Breast Neoplasms — 11 open to participants now, 25 under way, 4 of them phase 3. olaparib · Breast Neoplasms.

Enrollment
28th of 51
50 · median 54
Started
2022
with 6 others
Phase 2
24 of 51
7 open now
Registered
44th of 51
by date
Lead sponsor
11 of 51
AstraZeneca

Among the 51 studies testing olaparib in Breast Neoplasms, this one is the 28th largest by enrollment, is one of 7 that started in 2022, is one of 24 in phase 2, and was the 44th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 51 studies testing olaparib in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing olaparib in Breast Neoplasms, or all of them as a file.
02

Study summary

This study to learn more about olaparib and olaparib plus durvalumab combination therapy and also to better understand the studied disease, breast cancer, and associated health problems.

Olaparib is a type of drug called a PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitor. PARP inhibitors can destroy cancer cells that are not good at repairing DNA damage. Olaparib is also approved by US Food and Drug Administration (FDA), European Medicines Agency (EMA) and in other countries for treating women with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.

Durvalumab is a type of anticancer drug called immunotherapy that targets cancer cells by blocking the signal that prevents the immune system from seeing the cancer cell. Your immune system can then attack and kill the cancer cells. Durvalumab is approved by the FDA and the EMA for the treatment of patients with locally advanced non-small cell lung cancer after receiving chemoradiation therapy and extensive-stage small cell lung cancer in combination with chemotherapy .

Some parts of this study are experimental, which means that durvalumab and the combination of olaparib and durvalumab are still in the development stage for the treatment of breast cancer, and they are not approved for treatment of breast cancer, except for use in research studies like this.

Read the detailed description

The investigation of olaparib as monotherapy or olaparib in combination with durvalumab in patients with early stage BRCAm, oestrogen receptor (ER)-negative or ER-low, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who are candidates for neoadjuvant therapy supports the ongoing effort to identify novel agents and new drug combinations that can improve pathological complete response (pCR) rates and event-free survival (EFS). In patients at a lower risk (T1b-c/N0) of disease recurrence and a higher chance for cure, monotherapy olaparib may provide adequate neoadjuvant treatment. In contrast, monotherapy olaparib may be inadequate neoadjuvant treatment for those patients at a higher risk (T2/N0 or T1/N1) of recurrence, and the addition of an immune checkpoint inhibitor (ICI) to the neoadjuvant regimen may improve long-term outcomes as was seen in KEYNOTE-522 and GeparNuevo. However, the risk of irreversible immune-mediated adverse events (AEs) of the endocrine system due to ICI use supports the use of ICIs only in the cohort of patients at higher risk for disease recurrence. For both the lower and higher risk groups, the study treatments have the potential for the development of de-escalation strategies in this disease setting where traditional chemotherapy regimens may be avoided altogether.

While assessment of the efficacy of the combination of olaparib and durvalumab is ongoing, there are sufficient safety data available to develop a safety and tolerability profile for the combination.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • BRCA Mutations
  • Early Stage
  • HER2-Negative Breast Cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or Females ≥18 years
  • Minimum body weight of 30 kg
  • Capable of giving signed .
  • Male and Female participants of must use effective methods of
  • confirmed, newly diagnosed, primary, operable, nonmetastatic invasive breast cancer with the following characteristics:

    --ER-negative or ER-low defined as IHC nuclear staining ≤10%

  • -negative (not eligible for anti-HER2 therapy) defined as:

    • IHC 0, 1+ without in situ hybridization OR
    • In situ hybridization non-amplified with ratio less than 2.0 OR
    • In situ hybridization average HER2 copy number \< 6 signals/cells
  • Clinical TNM staging (per AJCC 8th Edition) as follows:

    • T1b (>5 mm but ≤10 mm), N0, no known (M0 or MX); OR
    • T1c (>10 mm but ≤20 mm), N0, no known metastases (M0 or MX); OR
    • T1 (>1 mm but ≤20 mm), N1, no known metastases (M0 or MX); OR
    • T2 (>20 mm but ≤50 mm), N0, no known metastases (M0 or MX).).
  • Documented deleterious or suspected deleterious mutation in BRCA1 or BRCA2 from local BRCA testing using either a germline or tumour test.
  • (ECOG) performance status of 0 or 1
  • Participants must have adequate organ and bone marrow function
  • Participant must be willing to undergo a baseline research prior to start of study treatment.
  • Participant must be willing to have any leftover tumour tissue/FFPE from the diagnostic biopsy submitted for research purposes, if available.

Exclusion criteria

Exclusion Criteria:

  • Any evidence of other diseases (such as severe or uncontrolled systemic diseases or active, uncontrolled infections, including but not limited to, uncontrolled ventricular arrhythmia, uncontrolled hypertension, recent [within 3 months] myocardial infarction, uncontrolled major seizure disorder, renal transplant, active bleeding diseases, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography scan
  • nausea and vomiting, chronic gastrointestinal disease likely to interfere with absorption of the study medication, inability to swallow the formulated product
  • History of another primary except for malignancy treated with curative intent with no known active disease for ≥5 years before the first dose of study intervention and of low potential risk for recurrence
  • Participants with MDS or AML
  • For higher risk (Cohort B) participants only: Active or prior documented or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, sarcoidosis, granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc), autoimmune pneumonitis, and autoimmune myocarditis
  • Known active hepatitis infection, positive antibody, virus surface antigen or hepatitis B virus core antibody
  • Known to have tested positive for unless currently on effective anti-retroviral therapy with an undetectable viral load within 6 months
  • History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment ( [CTCAE] Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia
  • Participant must not have had any prior treatment for the current breast cancer, including surgery, chemotherapy, hormonal therapy, radiation, or experimental therapy
  • For higher risk (Cohort B) participants only: Prior exposure to anti-PD1, , or anti-CTLA4 agents (ICIs); OR an agent directed to other co-inhibitory or co-stimulatory T-cell receptors
  • Any concurrent anticancer treatment
  • Major surgical procedure (excluding placement of vascular access, local surgery of isolated lesions, or diagnostic staging) within 2 weeks of the first dose of study intervention
  • For higher risk (Cohort B) participants only: Current or prior use of medication within 14 days before the first dose of durvalumab.
  • Concomitant use of:

    • Known strong cytochrome P450 () inhibitors or moderate CYP3A inhibitors within 2 weeks prior to first dose of study intervention
    • Known strong CYP3A inducers or moderate CYP3A inducers .The required prior to starting study therapy is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Cohort A

    Cohort A will consist of a lower-risk population of participants with HER2-negative ER-negative or ER-low defined as having a tumour size \>5 mm and ≤20 mm and N0 (T1b-c/N0).

    Drug: Neoadjuvant Olaparib monotherapy group

  • Experimental
    Cohort B

    Cohort B will consist of a higher-risk population of participants with HER2-negative ER-negative or ER-low defined as having a tumour size of \>20 mm but ≤50 mm and N0 (T2/N0), or having a tumour size of \>1 mm but ≤20 mm and N1 (T1/N1).

    Combination Product: Neoadjuvant combination therapy with olaparib plus durvalumab

Interventions

  • DrugNeoadjuvant Olaparib monotherapy group

    Neoadjuvant olaparib monotherapy (300 mg BID) for four to six 28-day cycles.

    Also known as: Cohort A

  • Combination productNeoadjuvant combination therapy with olaparib plus durvalumab

    Drug pages: Olaparib · Durvalumab

    Neoadjuvant combination therapy with olaparib (300 mg BID) plus durvalumab (1500 mg IV Q4W) for four to six 28-day cycles.

    Also known as: Cohort B

06

What researchers measure

Primary outcomes

  1. pCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, Assessed by Central Pathology Review

    pCR = pathological complete response pCR was defined as ypT0/Tis ypN0 (ie, no invasive residual in breast and the axillary lymph nodes on evaluation of the complete resected breast specimen and all sampled regional lymph nodes) following completion of neoadjuvant systemic therapy. Results of this outcome measure are from DCO1 (20 November 2024). The Clopper Pearson method is for the computation of the 95% confidence interval (CI).

    Time frame: Approx. 4 to 6 months

Secondary outcomes

  1. pCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, Assessed by Local Pathology Review

    pCR was defined as ypT0/Tis ypN0 (ie, no invasive residual in breast and the axillary lymph nodes on evaluation of the complete resected breast specimen and all sampled regional lymph nodes) following completion of neoadjuvant systemic therapy. Results of this outcome measure are from DCO1 (20 November 2024). The Clopper Pearson method is for the computation of the 95% CI.

    Time frame: Approx. 4 to 6 months

  2. RCB of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy as Assessed by Central Pathology Review

    RCB = residual cancer burden RCB index value using 6 variables to categorize response in 1 of 4 classes: RCB 0 (pCR), I (minimal RCB), II (moderate RCB), and III (extensive RCB). RCB III included patients who had clinical progression before surgery, and there was no central pCR performed. Results of this outcome measure are from DCO1 (20 November 2024).

    Time frame: Approx. 4 to 6 months

  3. RCB of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy as Assessed by Local Pathology Review

    RCB index value using 6 variables to categorize response in 1 of 4 classes: RCB 0 (pCR), I (minimal RCB), II (moderate RCB), and III (extensive RCB). RCB III included patients who had clinical progression before surgery, and there was no central pCR performed. Results of this outcome measure are from DCO1 (20 November 2024).

    Time frame: Approx. 4 to 6 months

  4. Percentage Change in Tumour Volume at Week 12 and Week 24 From Baseline

    Percentage change in tumour volume at Week 12 and Week 24 from baseline was measured using magnetic resonance imaging (MRI). Baseline was defined as the most recent measurement prior to the first administration of study intervention. Percent change from baseline was defined as: (Difference in value between post-baseline volume and baseline volume) divided by baseline volume and multiplied by 100. Results of this outcome measure are from DCO1 (20 November 2024).

    Time frame: Week 12 and Week 24

  5. Number of Participants With EFS (Event-free Survival)

    EFS was defined as time from the first dose of study intervention administration to any of the following events: progression of disease that precluded surgery, local or distant recurrence after surgery, second primary malignancy (breast or other invasive cancers), or death due to any cause. Results of this outcome measure are from final DCO (16 September 2025). One of 3 subjects in AZD2281 + MEDI4736 group had a disease progression recorded in error; 2 (8.0%) participants had an EFS event of progression of disease reported in the neoadjuvant period.

    Time frame: Approx. 3 years

  6. Number of Participants With AEs

    AE = adverse event; ECG = electrocardiogram Data included clinical observations, ECG parameters, haematology/clinical chemistry, vital signs assessed as the number of participants with AEs. Results of participants with AEs are from final DCO (16 September 2025).

    Time frame: Through study completion, approximately 34 months

  7. Number of Participants With SAEs

    SAE = serious adverse event Data included clinical observations, ECG parameters, haematology/clinical chemistry, vital signs assessed as the number of participants with AEs. Results of participants with SAEs are from final DCO (16 September 2025).

    Time frame: Through study completion, approximately 34 months

07

Results

Posted Sep 25, 2026
Limitations and caveats
The study was closed earlier than originally planned by the sponsor as the proof-of-concept primary endpoint of pCR rate and safety data available at DCO1 have been analysed and reported previously. Additionally, all participants were off study treatment and had completed post-treatment safety follow-up on 17 July 2025. The decision of early study closure was aligned with the scientific and ethical standards.

Participant flow

A total of 114 participants were screened from 28 study sites across 9 countries. Of these, 50 participants were enrolled.

Participant flow — Overall Study
MilestoneAZD2281AZD2281+MEDI4736
Started2525
Completed00
Not completed2525
Withdrew: Site terminated by sponsor22
Withdrew: Study terminated by sponsor2322
Withdrew: Withdrawal by subject01

Outcome measures

PrimarypCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, Assessed by Central Pathology Review

pCR = pathological complete response pCR was defined as ypT0/Tis ypN0 (ie, no invasive residual in breast and the axillary lymph nodes on evaluation of the complete resected breast specimen and all sampled regional lymph nodes) following completion of neoadjuvant systemic therapy. Results of this outcome measure are from DCO1 (20 November 2024). The Clopper Pearson method is for the computation of the 95% confidence interval (CI).

Time frame:
Approx. 4 to 6 months
Reported as:
Mean · Percentage
pCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, Assessed by Central Pathology Review
PercentageAZD2281AZD2281+MEDI4736
pCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, Assessed by Central Pathology Review68.0 (46.50 to 85.05)80.0 (59.30 to 93.17)
SecondarypCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, Assessed by Local Pathology Review

pCR was defined as ypT0/Tis ypN0 (ie, no invasive residual in breast and the axillary lymph nodes on evaluation of the complete resected breast specimen and all sampled regional lymph nodes) following completion of neoadjuvant systemic therapy. Results of this outcome measure are from DCO1 (20 November 2024). The Clopper Pearson method is for the computation of the 95% CI.

Time frame:
Approx. 4 to 6 months
Reported as:
Mean · Percentage
pCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, Assessed by Local Pathology Review
PercentageAZD2281AZD2281+MEDI4736
pCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, Assessed by Local Pathology Review68.0 (46.50 to 85.05)76.0 (54.87 to 90.64)
SecondaryRCB of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy as Assessed by Central Pathology Review

RCB = residual cancer burden RCB index value using 6 variables to categorize response in 1 of 4 classes: RCB 0 (pCR), I (minimal RCB), II (moderate RCB), and III (extensive RCB). RCB III included patients who had clinical progression before surgery, and there was no central pCR performed. Results of this outcome measure are from DCO1 (20 November 2024).

Time frame:
Approx. 4 to 6 months
Reported as:
Count of participants · Participants
RCB of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy as Assessed by Central Pathology Review
ParticipantsAZD2281AZD2281+MEDI4736
RCB-01720
RCB-I11
RCB-II61
RCB-III12
Missing01
SecondaryRCB of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy as Assessed by Local Pathology Review

RCB index value using 6 variables to categorize response in 1 of 4 classes: RCB 0 (pCR), I (minimal RCB), II (moderate RCB), and III (extensive RCB). RCB III included patients who had clinical progression before surgery, and there was no central pCR performed. Results of this outcome measure are from DCO1 (20 November 2024).

Time frame:
Approx. 4 to 6 months
Reported as:
Count of participants · Participants
RCB of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy as Assessed by Local Pathology Review
ParticipantsAZD2281AZD2281+MEDI4736
RCB-01719
RCB-I22
RCB-II50
RCB-III12
Missing02
SecondaryPercentage Change in Tumour Volume at Week 12 and Week 24 From Baseline

Percentage change in tumour volume at Week 12 and Week 24 from baseline was measured using magnetic resonance imaging (MRI). Baseline was defined as the most recent measurement prior to the first administration of study intervention. Percent change from baseline was defined as: (Difference in value between post-baseline volume and baseline volume) divided by baseline volume and multiplied by 100. Results of this outcome measure are from DCO1 (20 November 2024).

Time frame:
Week 12 and Week 24
Reported as:
Mean · Percentage in tumour volume
Percentage Change in Tumour Volume at Week 12 and Week 24 From Baseline
Percentage in tumour volumeAZD2281AZD2281+MEDI4736
Percentage change from baseline at Week 12-87.86 ± 17.527-84.49 ± 29.998
Percentage change from baseline at Week 24-42.32 ± 227.333-89.87 ± 34.726
SecondaryNumber of Participants With EFS (Event-free Survival)

EFS was defined as time from the first dose of study intervention administration to any of the following events: progression of disease that precluded surgery, local or distant recurrence after surgery, second primary malignancy (breast or other invasive cancers), or death due to any cause. Results of this outcome measure are from final DCO (16 September 2025). One of 3 subjects in AZD2281 + MEDI4736 group had a disease progression recorded in error; 2 (8.0%) participants had an EFS event of progression of disease reported in the neoadjuvant period.

Time frame:
Approx. 3 years
Reported as:
Count of participants · Participants
Number of Participants With EFS (Event-free Survival)
ParticipantsAZD2281AZD2281+MEDI4736
Number of Participants With EFS (Event-free Survival)33
SecondaryNumber of Participants With AEs

AE = adverse event; ECG = electrocardiogram Data included clinical observations, ECG parameters, haematology/clinical chemistry, vital signs assessed as the number of participants with AEs. Results of participants with AEs are from final DCO (16 September 2025).

Time frame:
Through study completion, approximately 34 months
Reported as:
Count of participants · Participants
Number of Participants With AEs
ParticipantsAZD2281AZD2281+MEDI4736
Number of Participants With AEs2424
SecondaryNumber of Participants With SAEs

SAE = serious adverse event Data included clinical observations, ECG parameters, haematology/clinical chemistry, vital signs assessed as the number of participants with AEs. Results of participants with SAEs are from final DCO (16 September 2025).

Time frame:
Through study completion, approximately 34 months
Reported as:
Count of participants · Participants
Number of Participants With SAEs
ParticipantsAZD2281AZD2281+MEDI4736
Number of Participants With SAEs45

Adverse events

Collected over AEs were collected from the time of informed consent form signature through study completion, approximately 34 months (final DCO: 16 September 2025).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD22810/25 (0%)4/25 (16%)23/25 (92%)
AZD2281+MEDI47360/25 (0%)5/25 (20%)23/25 (92%)
Most frequent serious events
Most frequent serious events
EventAZD2281AZD2281+MEDI4736
AnaemiaBlood and lymphatic system disorders2/250/25
Pelvic massGeneral disorders1/250/25
HypersensitivityImmune system disorders0/251/25
BronchitisInfections and infestations0/251/25
Post procedural infectionInfections and infestations0/251/25
Alanine aminotransferase increasedInvestigations0/251/25
Aspartate aminotransferase increasedInvestigations0/251/25
Diabetes mellitusMetabolism and nutrition disorders0/251/25
Transient ischaemic attackNervous system disorders0/251/25
Internal device exposedProduct Issues1/251/25
Most frequent other events
Showing 10 of 44
Most frequent other events
EventAZD2281AZD2281+MEDI4736
NauseaGastrointestinal disorders15/2519/25
FatigueGeneral disorders9/2513/25
DiarrhoeaGastrointestinal disorders10/259/25
AstheniaGeneral disorders10/258/25
AnaemiaBlood and lymphatic system disorders10/259/25
DysgeusiaNervous system disorders8/254/25
HeadacheNervous system disorders8/258/25
HypothyroidismEndocrine disorders0/257/25
VomitingGastrointestinal disorders3/255/25
PyrexiaGeneral disorders2/255/25

Baseline characteristics

Full Analysis Set: Included all enrolled participants who received at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)AZD2281AZD2281+MEDI4736Total
Mean47.8 ± 10.3247.2 ± 14.2447.5 ± 12.31
Age, Customized
Age, Customized(Participants)AZD2281AZD2281+MEDI4736Total
< 30011
30 - 396814
40 - 4911819
50 - 59336
60 - 69538
>= 70022
Sex: Female, Male
Sex: Female, Male(Participants)AZD2281AZD2281+MEDI4736Total
Female252550
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AZD2281AZD2281+MEDI4736Total
Hispanic or Latino202
Not Hispanic or Latino232548
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AZD2281AZD2281+MEDI4736Total
Black or African American112
Native Hawaiian or Other Pacific Islander000
American Indian or Alaska Native000
Asian011
White242044
Other033
Not reported000
Region of Enrollment
Region of Enrollment(Participants)AZD2281AZD2281+MEDI4736Total
Spain13922
Germany5510
United States224
Australia123
Belgium123
Italy123
Austria112
Israel112
United Kingdom011
Height
Height(cm)AZD2281AZD2281+MEDI4736Total
Mean162.3 ± 6.55162.3 ± 6.67162.3 ± 6.54
Weight
Weight(kg)AZD2281AZD2281+MEDI4736Total
Mean68.29 ± 15.76769.38 ± 12.38068.83 ± 14.040

1 further baseline measures are reported on the registry.

08

Study locations

36 sites
  • Research Site
    Loveland, Colorado 80537, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    East Melbourne, 3002, Australia
  • Research Site
    Rankweil, 6830, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Augsburg, by, 86156, Germany
  • Research Site
    Cologne, 50931, Germany
  • Research Site
    Essen, 45130, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Kfar Saba, 44218, Israel
  • Research Site
    Ramat Gan, 5262000, Israel
  • Research Site
    Rehovot, 76100, Israel
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Modena, 41124, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    A Coruña, 15006, Spain
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Cáceres, 10003, Spain
  • Research Site
    Hospitalet deLlobregat, 08907, Spain
  • Research Site
    Lleida, 25198, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Seville, 41009, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Valencia, 46010, Spain
  • Research Site
    Nottingham, NG5 1PB, United Kingdom
09

References and documents

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Nov 2024, 24 months.

Results were first posted in Sep 2026, 1 year 10 months after primary completion. A results delay was requested in Aug 2025.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 24 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Sep 2025, on Sep 25, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2022
First posted
Aug 11, 2022
StartActual
Nov 7, 2022
Primary completionActual
Nov 20, 2024
CompletionActual
Sep 16, 2025was Dec 2026
Results delay requested
Aug 6, 2025
Results first posted
Sep 25, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 25, 2026
Results
Results posted
posted Sep 25, 2026
Sites
1 site added, 2 sites removed
Show site
  • Research Site · East Melbourne, Australia
Show 2 removed
  • Research Site · Greeley, United States
  • Research Site · Melbourne, Australia
Sep 25, 2026
Study completion
Dec 31, 2026→Sep 16, 2025 (actual)
Sep 25, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedTo evaluate the efficacypCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, measuredAssessed by pCR (pathological complete response) rate, of olaparib monotherapy and olaparib plus durvalumab combination therapy, as assessed by central pathology review.Central Pathology ReviewTime frame: Approx. 4 to 6 months
Sep 25, 2026
Secondary outcomes
3 edited, 4 added, 11 removed
What changed in the outcomes
  • EditedTo evaluate the efficacypCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, measuredAssessed by pCR rate, of olaparib monotherapy and olaparib plus durvalumab combination therapy as assessed by local pathology reviewLocal Pathology ReviewTime frame: Approx. 4 to 6 months
  • EditedTo evaluate the efficacy, measuredRCB of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy as Assessed by RCB (residual cancer burden), of olaparib monotherapy and olaparib plus durvalumab combination therapy as assessed by central pathology reviewCentral Pathology ReviewTime frame: Approx. 4 to 6 months
  • EditedTo evaluate the efficacy, measuredRCB of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy as Assessed by RCB, of olaparib monotherapy and olaparib plus durvalumab combination therapy as assessed by local pathology reviewLocal Pathology ReviewTime frame: Approx. 4 to 6 months
  • AddedPercentage Change in Tumour Volume at Week 12 and Week 24 From BaselineTime frame: Week 12 and Week 24
  • AddedNumber of Participants With EFS (Event-free Survival)Time frame: Approx. 3 years
  • AddedNumber of Participants With AEsTime frame: Through study completion, approximately 34 months
  • AddedNumber of Participants With SAEsTime frame: Through study completion, approximately 34 months
  • RemovedTo evaluate the efficacy of olaparib monotherapy and olaparib plus durvalumab combination therapy in terms of change from baseline tumour volume. Tumour volume will be assessed by local radiology review.Time frame: Approx. 4 to 6 months
  • RemovedTo evaluate the efficacy of olaparib monotherapy and olaparib plus durvalumab combination therapy in terms of change from baseline tumour volume. Tumour volume will be assessed by local radiology review.Time frame: Approx. 4 to 6 months
  • RemovedTo evaluate the efficacy of olaparib monotherapy and olaparib plus durvalumab combination therapy by assessment of EFS (event-free survival).Time frame: Approx. 3 years
  • RemovedSafety and tolerability profile of olaparib monotherapy and olaparib plus durvalumab combination therapy by assessment of advers events and seriuos advers events (AEs/SAEs)Time frame: Through study completion, around 15 months for single patient
  • RemovedThe number of participants with adverse events /serious adverse events of olaparib monotherapy and olaparib plus durvalumab combination therapy.Time frame: Through study completion, around 15 months for single patient
  • RemovedSafety and tolerability profile of olaparib monotherapy when given as adjuvant therapy to participants who achieve pCR by assessment of AEs/SAEsTime frame: Through study completion, around 15 months for single patient
  • RemovedThe number of participants with adverse events / serious adverse events of olaparib monotherapy when given as adjuvant therapy to participants who achieve pCR.Time frame: Through study completion, around 15 months for single patient
  • RemovedSystolic blood pressure (SBP), diastolic blood pressure (DBP)Time frame: Through study completion, around 15 months for single patient
  • RemovedBody TemperatureTime frame: Through study completion, around 15 months for single patient
  • RemovedPulse rate (heart rate)Time frame: Through study completion, around 15 months for single patient
  • RemovedWeightTime frame: Through study completion, around 15 months for single patient
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Active, not recruiting→Completed
    Results posted
    1 site added, 2 sites removed
    Show site
    • Research Site · East Melbourne, Australia
    Show 2 removed
    • Research Site · Greeley, United States
    • Research Site · Melbourne, Australia
    Study completion Dec 31, 2026→Sep 16, 2025 (now actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedTo evaluate the efficacypCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, measuredAssessed by pCR (pathological complete response) rate, of olaparib monotherapy and olaparib plus durvalumab combination therapy, as assessed by central pathology review.Central Pathology ReviewTime frame: Approx. 4 to 6 months
    Secondary outcomes 3 edited, 4 added, 11 removed
    What changed in the outcomes
    • EditedTo evaluate the efficacypCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, measuredAssessed by pCR rate, of olaparib monotherapy and olaparib plus durvalumab combination therapy as assessed by local pathology reviewLocal Pathology ReviewTime frame: Approx. 4 to 6 months
    • EditedTo evaluate the efficacy, measuredRCB of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy as Assessed by RCB (residual cancer burden), of olaparib monotherapy and olaparib plus durvalumab combination therapy as assessed by central pathology reviewCentral Pathology ReviewTime frame: Approx. 4 to 6 months
    • EditedTo evaluate the efficacy, measuredRCB of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy as Assessed by RCB, of olaparib monotherapy and olaparib plus durvalumab combination therapy as assessed by local pathology reviewLocal Pathology ReviewTime frame: Approx. 4 to 6 months
    • AddedPercentage Change in Tumour Volume at Week 12 and Week 24 From BaselineTime frame: Week 12 and Week 24
    • AddedNumber of Participants With EFS (Event-free Survival)Time frame: Approx. 3 years
    • AddedNumber of Participants With AEsTime frame: Through study completion, approximately 34 months
    • AddedNumber of Participants With SAEsTime frame: Through study completion, approximately 34 months
    • RemovedTo evaluate the efficacy of olaparib monotherapy and olaparib plus durvalumab combination therapy in terms of change from baseline tumour volume. Tumour volume will be assessed by local radiology review.Time frame: Approx. 4 to 6 months
    • RemovedTo evaluate the efficacy of olaparib monotherapy and olaparib plus durvalumab combination therapy in terms of change from baseline tumour volume. Tumour volume will be assessed by local radiology review.Time frame: Approx. 4 to 6 months
    • RemovedTo evaluate the efficacy of olaparib monotherapy and olaparib plus durvalumab combination therapy by assessment of EFS (event-free survival).Time frame: Approx. 3 years
    • RemovedSafety and tolerability profile of olaparib monotherapy and olaparib plus durvalumab combination therapy by assessment of advers events and seriuos advers events (AEs/SAEs)Time frame: Through study completion, around 15 months for single patient
    • RemovedThe number of participants with adverse events /serious adverse events of olaparib monotherapy and olaparib plus durvalumab combination therapy.Time frame: Through study completion, around 15 months for single patient
    • RemovedSafety and tolerability profile of olaparib monotherapy when given as adjuvant therapy to participants who achieve pCR by assessment of AEs/SAEsTime frame: Through study completion, around 15 months for single patient
    • RemovedThe number of participants with adverse events / serious adverse events of olaparib monotherapy when given as adjuvant therapy to participants who achieve pCR.Time frame: Through study completion, around 15 months for single patient
    • RemovedSystolic blood pressure (SBP), diastolic blood pressure (DBP)Time frame: Through study completion, around 15 months for single patient
    • RemovedBody TemperatureTime frame: Through study completion, around 15 months for single patient
    • RemovedPulse rate (heart rate)Time frame: Through study completion, around 15 months for single patient
    • RemovedWeightTime frame: Through study completion, around 15 months for single patient
    + 5 other changes: identifiers, verification date, registry dates, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05498155
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 11, 2022
Start date
Nov 7, 2022
Primary completion
Nov 20, 2024
Completion
Sep 16, 2025
Results posted
Sep 25, 2026
Last update
Sep 25, 2026

Study contacts

Anitra Fielding, MBChB
study director · AstraZeneca

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Olaparib · Durvalumab

Start the discussion